Clinical Trials - OPK

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT05543928Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary HyperparathyroidismTERMINATEDPHASE32023-01-312024-06-192024-06-19
NCT04551911Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19COMPLETEDPHASE22020-11-022021-10-082021-10-08
NCT04063644Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye PatientsCOMPLETEDNA2019-05-302020-12-222020-12-22
NCT03810664A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product PresentationsCOMPLETEDPHASE12019-01-182019-04-192019-04-19
NCT03660800Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy SubjectsCOMPLETEDPHASE12018-08-202019-01-222018-10-24
NCT03602261Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDITERMINATEDPHASE22018-07-092021-02-242021-02-24
NCT03588884Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D InsufficiencyCOMPLETEDPHASE42018-06-082020-04-242020-04-24
NCT03406377Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes SubjectsCOMPLETEDPHASE22018-04-022019-06-272019-03-08
NCT03297398Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)TERMINATEDPHASE22018-02-212019-06-102019-04-18
NCT03762408Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis.COMPLETEDNA2017-12-152020-05-292020-05-29
NCT03874013Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone DeficiencyCOMPLETEDPHASE32017-12-072020-03-062020-03-06
NCT02919800A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult MaleCOMPLETEDPHASE12017-01-222018-02-212018-02-21
NCT02968004Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCOMPLETEDPHASE32016-122024-052019-08
NCT02692781A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese SubjectsCOMPLETEDPHASE12016-022016-12-152016-12-15
NCT02418793A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or BCOMPLETEDPHASE12015-052018-092018-09
NCT03355651Efficacy and Tolerability of a Nutritional Supplement, Plactive Progen, in ACL ReconstructionCOMPLETEDNA2015-03-092017-03-032017-02-01
NCT02418767Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese VolunteersCOMPLETEDPHASE12015-012015-062015-03
NCT02274623Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic AcidCOMPLETEDPHASE12014-122017-03-172017-02-27
NCT02188303A Study of LY2944876 in Healthy Japanese and Non-Japanese ParticipantsTERMINATEDPHASE12014-072014-122014-12
NCT02119819A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 DiabetesCOMPLETEDPHASE22014-042015-102015-08
NCT02500316Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCOMPLETEDPHASE22014-022023-112023-11
NCT01791725A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without DementiaCOMPLETEDPHASE22013-092014-062014-06
NCT01909479A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone DeficiencyTERMINATEDPHASE32013-062018-082016-08
NCT02282813Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002COMPLETEDPHASE32013-042015-052015-05
NCT01766336A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's DiseaseTERMINATEDPHASE22013-012015-082015-08
NCT01453634Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)WITHDRAWNPHASE22013-012013-072013-07
NCT01704079Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCOMPLETEDPHASE32012-112014-092014-08
NCT01735630Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's DiseaseCOMPLETEDPHASE22012-112015-052015-05
NCT01651000Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCOMPLETEDPHASE32012-092014-072014-07
NCT01674010Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I DisorderTERMINATEDPHASE22012-082014-062014-06
NCT01592500Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCOMPLETEDPHASE22012-022015-072015-07
NCT01357421Effects of TT301 on Cytokine Levels Post Endotoxin ChallengeCOMPLETEDPHASE12011-052011-062011-06
NCT01219855Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)COMPLETEDPHASE2, PHASE32010-102011-112011-11
NCT01225666MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)COMPLETEDPHASE22010-082012-042011-07
NCT00557791Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)WITHDRAWNPHASE32009-112012-072011-07
NCT01060722MOD-4023 Study in Healthy Male VolunteersCOMPLETEDPHASE12009-102010-012010-01
NCT00934050ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's DiseaseCOMPLETEDPHASE22009-062011-062011-06
NCT00888069Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease SubjectsCOMPLETEDPHASE12009-052009-122009-11
NCT00834223A Prospective, Multicenter, Open-label, Safety and Preliminary Efficacy Study of the Surgical Implantation of OPKO's Glaucoma Drainage Device (AquashuntTM) in Patients With Refractory Chronic Forms of Open Angle Glaucoma (OAG)COMPLETEDNA2009-012010-052009-09
NCT00792857Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)COMPLETEDPHASE12008-112009-102009-09
NCT00742716Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney DiseaseCOMPLETEDPHASE22008-102010-062010-02
NCT00743002A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or ThiazolidinedioneCOMPLETEDPHASE22008-082009-122009-12
NCT00568776ELND005 in Patients With Mild to Moderate Alzheimer's DiseaseCOMPLETEDPHASE22007-122010-052010-05
NCT00499590Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMDTERMINATEDPHASE32007-082009-052009-03
NCT00384098Safety and Efficacy of Topically Applied CTA018 in Plaque PsoriasisCOMPLETEDPHASE22006-092007-052007-05
NCT00306904Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular EdemaCOMPLETEDPHASE22006-012007-122007-09
NCT00239187A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1COMPLETEDPHASE12005-092007-01
NCT00230854Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and RibavirinCOMPLETEDPHASE12005-082007-07
NCT00259753Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular DegenerationCOMPLETEDPHASE22005-072007-122007-12
NCT00239148A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1COMPLETEDPHASE12005-062006-12
NCT00722384Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5COMPLETEDPHASE12004-082007-122007-08